- Home
- SKYE vs TLSI Comparison
SKYE vs TLSI Comparison
Compare SKYE & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- TLSI
- Stock Information
- Founded
- SKYE 2012
- TLSI 2010
- Country
- SKYE United States
- TLSI United States
- Employees
- SKYE N/A
- TLSI N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- TLSI Medical Specialities
- Sector
- SKYE Health Care
- TLSI Health Care
- Exchange
- SKYE Nasdaq
- TLSI Nasdaq
- Market Cap
- SKYE 73.4M
- TLSI 204.0M
- IPO Year
- SKYE N/A
- TLSI N/A
- Fundamental
- Price
- SKYE $4.52
- TLSI $5.07
- Analyst Decision
- SKYE Buy
- TLSI Strong Buy
- Analyst Count
- SKYE 6
- TLSI 5
- Target Price
- SKYE $16.60
- TLSI $10.90
- AVG Volume (30 Days)
- SKYE 2.0M
- TLSI 154.9K
- Earning Date
- SKYE 08-08-2025
- TLSI 08-13-2025
- Dividend Yield
- SKYE N/A
- TLSI N/A
- EPS Growth
- SKYE N/A
- TLSI N/A
- EPS
- SKYE N/A
- TLSI N/A
- Revenue
- SKYE N/A
- TLSI $32,141,000.00
- Revenue This Year
- SKYE N/A
- TLSI $55.52
- Revenue Next Year
- SKYE N/A
- TLSI $54.76
- P/E Ratio
- SKYE N/A
- TLSI N/A
- Revenue Growth
- SKYE N/A
- TLSI 46.20
- 52 Week Low
- SKYE $1.14
- TLSI $3.50
- 52 Week High
- SKYE $7.60
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- SKYE 74.70
- TLSI 45.72
- Support Level
- SKYE $3.41
- TLSI $4.81
- Resistance Level
- SKYE $5.75
- TLSI $5.63
- Average True Range (ATR)
- SKYE 0.60
- TLSI 0.35
- MACD
- SKYE 0.17
- TLSI -0.03
- Stochastic Oscillator
- SKYE 69.27
- TLSI 30.95
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.